Your browser doesn't support javascript.
loading
Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis.
Macaluso, Claudio; Boccabella, Cristina; Kokosi, Maria; Sivarasan, Nishanth; Kouranos, Vasilis; George, Peter M; Margaritopoulos, George; Molyneaux, Philip L; Chua, Felix; Maher, Toby M; Jenkins, Gisli R; Nicholson, Andrew G; Desai, Sujal R; Devaraj, Anand; Wells, Athol U; Renzoni, Elisabetta A; Stock, Carmel J W.
Afiliación
  • Macaluso C; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Boccabella C; Department of Pneumology, INRCA/IRCCS, "L.Mandic" Hospital Merate (LC), Merate, Italy.
  • Kokosi M; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Sivarasan N; Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, University of the Sacred Heart, Rome, Italy.
  • Kouranos V; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • George PM; Department of Radiology, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Margaritopoulos G; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Molyneaux PL; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Chua F; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.
  • Maher TM; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Jenkins GR; ILD Unit, London North West University Hospital Healthcare Trust, London, UK.
  • Nicholson AG; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Desai SR; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Devaraj A; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.
  • Wells AU; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Renzoni EA; Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Stock CJW; Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Respirology ; 27(3): 202-208, 2022 03.
Article en En | MEDLINE | ID: mdl-35023231
ABSTRACT
BACKGROUND AND

OBJECTIVE:

A proportion of patients with fibrotic hypersensitivity pneumonitis (fHP) follow a progressive disease course despite immunosuppressive treatment. Little is known about predictors of mortality in fHP. We aimed to investigate the impact of short-term lung function changes in fHP on mortality.

METHODS:

Baseline demographics for 145 consecutive patients with a multi-disciplinary team diagnosis of fHP, as well as baseline and 1-year follow-up of lung function, baseline echocardiographic findings, bronchoalveolar lavage (BAL) cellularity and all-cause mortality were recorded. Changes in forced vital capacity (FVC) ≥ 5% and ≥10%, and diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 10% and ≥15% at 1 year were calculated. Cox proportional hazards analysis was performed to test for associations with mortality.

RESULTS:

Baseline lung function severity, age, presence of honeycombing on computed tomography (CT) and echocardiographic pulmonary arterial systolic pressure (PASP) ≥ 40 mm Hg were associated with early mortality, while BAL lymphocytosis was associated with improved survival. A decline in FVC ≥ 5% (hazard ratio [HR] 3.10, 95% CI 2.00-4.81, p < 0.001), FVC ≥ 10% (HR 3.11, 95% CI 1.94-4.99, p < 0.001), DLCO ≥ 10% (HR 2.80, 95% CI 1.78-4.42, p < 0.001) and DLCO ≥ 15% (HR 2.92, 95% CI 1.18-4.72, p < 0.001) at 1 year was associated with markedly reduced survival on univariable and multivariable analyses after correcting for demographic variables, disease severity, honeycombing on CT and treatment, as well as BAL lymphocytosis and PASP ≥ 40 mm Hg on echocardiography, in separate models.

CONCLUSION:

Worsening in FVC and DLCO at 1 year, including a marginal decline in FVC ≥ 5% and DLCO ≥ 10%, is predictive of markedly reduced survival in fHP.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alveolitis Alérgica Extrínseca / Linfocitosis Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Respirology Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alveolitis Alérgica Extrínseca / Linfocitosis Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Respirology Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
...